SAN DIEGO—(BUSINESS WIRE)—Dec. 6, 2007—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will host a live webcast of its Analyst and Investor Meeting to beheld in New York City on Friday, December 14, 2007, from 8:00 a.m. to10:30 a.m. Eastern Time.
The program will feature presentations by ACADIA management andleading clinicians and will include an overview of the therapeuticareas of schizophrenia and Parkinson's disease psychosis as well as apresentation of data from ACADIA's Phase II schizophrenia co-therapytrial with pimavanserin and a review of ACADIA's Phase III programwith pimavanserin for Parkinson's disease psychosis, its Phase IIprogram with ACP-104 for schizophrenia, and other discovery anddevelopment activities.
To access the webcast, please log onto ACADIA's website atwww.acadia-pharm.com and click on to the investors sectionapproximately 10 minutes prior to the start of the webcast to allowfor any software downloads that may be necessary. An archivedrecording of the event will be available on ACADIA's website throughDecember 28, 2007.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive mid-to-late stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at diseases with large unmetmedical needs, including schizophrenia, Parkinson's disease psychosis,sleep maintenance insomnia, and neuropathic pain. All of the drugcandidates in ACADIA's product pipeline emanate from discoveries madeusing its proprietary drug discovery platform. ACADIA's corporateheadquarters is located in San Diego, California and it maintainsresearch and development operations in both San Diego and Malmo,Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.Lisa Barthelemy, Director, Investor RelationsThomas H. Aasen, Vice President andChief Financial Officer858-558-2871SOURCE: ACADIA Pharmaceuticals Inc.